Clinical trial
Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV…
NCT00471471 · Ahmad Tarhini, Other · Completed
Key facts
| NCT number | NCT00471471 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery |
| Official title | Safety and Immunogenicity of Vaccination With Multi-Epitope Peptide Vaccine Containing MART-1, gp100, and Tyrosinase Peptides Given With the Combination of GMCSF and CpG Oligonucleotide (CpG 7909) in ISA-Oil Adjuvant for Patients With Recurrent Inoperable Stage III or Stage IV Melanoma |
| Lead sponsor | Ahmad Tarhini, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Intraocular Melanoma, Malignant Conjunctival Neoplasm, Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | Peptide vaccine, GM-CSF, PF3512676 |
| Enrollment | 22 |
| Start date | Oct 1, 2008 |
| Primary completion | Dec 1, 2011 |
| Completion | Dec 1, 2011 |
| First posted | May 10, 2007 |
| Last update posted | Jun 22, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: